Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/13/2025 | $55.00 → $75.00 | Market Perform → Outperform | Leerink Partners |
2/12/2025 | Neutral → Overweight | Cantor Fitzgerald | |
1/30/2025 | Hold → Buy | Edward Jones | |
12/3/2024 | $66.00 | Hold → Buy | Deutsche Bank |
11/18/2024 | $60.00 → $66.00 | Equal Weight → Overweight | Wells Fargo |
10/10/2024 | $63.00 → $82.00 | Equal Weight → Overweight | Barclays |
10/4/2024 | $59.00 → $85.00 | Hold → Buy | TD Cowen |
5/30/2024 | $61.00 | Neutral | Robert W. Baird |
Leerink Partners upgraded CVS Health from Market Perform to Outperform and set a new price target of $75.00 from $55.00 previously
Cantor Fitzgerald upgraded CVS Health from Neutral to Overweight
Edward Jones upgraded CVS Health from Hold to Buy
13F-HR - CVS HEALTH Corp (0000064803) (Filer)
10-K - CVS HEALTH Corp (0000064803) (Filer)
8-K - CVS HEALTH Corp (0000064803) (Filer)
WOONSOCKET, R.I., Dec. 3, 2024 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that Len Shankman will be president, Pharmacy and Consumer Wellness (PCW), reporting to Prem Shah, group president, CVS Health. In addition, the company announced the appointment of Lucille Accetta, RPh, MPH, MBA as chief pharmacy officer, also reporting to Shah. Both appointments are effective immediately. As president, Pharmacy and Consumer Wellness, Shankman will oversee the front store and retail pharmacy businesses across the company's more than 9,000 CVS Pharmacy locations. In his new
CVS Health Board of Directors appoints four new members: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman Appointments follow productive engagement with Glenview Capital Management WOONSOCKET, R.I., Nov. 18, 2024 /PRNewswire/ -- The Board of Directors of CVS Health (NYSE:CVS) today announced the appointment of four new board members: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman, following productive discussions with Glenview Capital Management. "In our discussions with the leadership at Glenview, we agreed that we can deliver greater value from our
Prem Shah named Group President, CVS Health; Steve Nelson named President, Aetna WOONSOCKET, R.I., Nov. 6, 2024 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced Prem Shah will be Group President, and will continue to report to David Joyner, President and Chief Executive Officer. In addition, the company announced the appointment of Steve Nelson as President, Aetna, and he will also report to Joyner. Both appointments are effective today. As Group President, Shah will be responsible for the operational performance and integrated value creation across CVS Caremark, CVS Pha
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced Karen S. Lynch has been elected to its board of directors, effective February 19, 2025. The appointment brings the total number of Thermo Fisher board members to 12. Ms. Lynch is a seasoned health care executive with over three decades of experience in the industry. As the former president and chief executive officer of CVS Health Corporation (NYSE:CVS), a leading health solutions company, she was responsible for leading more than 300,000 employees. Under Ms. Lynch's leadership, CVS Health touched the lives of more than 120 million consumers through its health care benefits and pharmacy benefits
WOONSOCKET, R.I., Feb. 17, 2025 /PRNewswire/ -- Today, CVS Health® (NYSE: CVS) named Ed DeVaney president of the company's CVS Caremark pharmacy benefit management business. He was named interim president in December 2024. DeVaney will report to Prem Shah, group president, CVS Health. "Ed's ability to build and grow a strong team culture, while prioritizing talent development, leads to strong business results," said CVS Health president and CEO, David Joyner. "His commitment shows every day in his deep understanding of our industry, his advocacy for our business, and a proven
Fourth Quarter Highlights Total revenues increased to $97.7 billion, up 4.2% compared to prior yearGAAP diluted EPS of $1.30 and Adjusted EPS of $1.19Full-Year Highlights Total revenues increased to $372.8 billion, up 4.2% compared to prior yearGAAP diluted EPS of $3.66 and Adjusted EPS of $5.42Generated cash flow from operations of $9.1 billion2025 Full-Year Guidance GAAP diluted EPS guidance range of $4.58 to $4.83Adjusted EPS guidance range of $5.75 to $6.00Cash flow from operations guidance of approximately $6.5 billionCEO Commentary"Our integrated model allows us to uniquely deliver a simpler, connected experience that saves time, saves money, and improves health. We have continued to s
4 - CVS HEALTH Corp (0000064803) (Issuer)
4/A - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
4 - CVS HEALTH Corp (0000064803) (Issuer)
SC 13G - CVS HEALTH Corp (0000064803) (Subject)
SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)
SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)
Fourth Quarter Highlights Total revenues increased to $97.7 billion, up 4.2% compared to prior yearGAAP diluted EPS of $1.30 and Adjusted EPS of $1.19Full-Year Highlights Total revenues increased to $372.8 billion, up 4.2% compared to prior yearGAAP diluted EPS of $3.66 and Adjusted EPS of $5.42Generated cash flow from operations of $9.1 billion2025 Full-Year Guidance GAAP diluted EPS guidance range of $4.58 to $4.83Adjusted EPS guidance range of $5.75 to $6.00Cash flow from operations guidance of approximately $6.5 billionCEO Commentary"Our integrated model allows us to uniquely deliver a simpler, connected experience that saves time, saves money, and improves health. We have continued to s
WOONSOCKET, R.I., Jan. 13, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) will hold a conference call with analysts and investors on Wednesday, February 12th, 2025, at 8:00 a.m. ET to discuss fourth quarter and full year 2024 financial results. An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website at investors.cvshealth.com where it will be archived for a period of one year. About CVS Health CVS Health® is the leading health solutions company, broadening access to care for millions of people nationwide. We improve the health of communities across America through our local presence, digital channels and with over 300,000 dedica
WOONSOCKET, R.I., Jan. 3, 2025 /PRNewswire/ -- CVS Health (NYSE:CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) per share on the Common Stock of the Corporation. The dividend is payable on February 3, 2025, to holders of record on January 23, 2025. About CVS HealthCVS Health® is a leading health solutions company building a world of health around every consumer it serves and connecting care so that it works for people wherever they are. As of September 30, 2024, the Company had more than 9,000 retail locations, more than 900 walk-in medical clinics, more than 225 primary care medical clinics, a leading pharmacy b